S-1 and Irinotecan Plus Bevacizumab As Second-line Chemotherapy for Patients with Oxaliplatin-refractory Metastatic Colorectal Cancer: a Multicenter Phase II Study in Japan (KSCC1102)
Overview
Authors
Affiliations
Background: Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan. However, there are few alternative practical second-line therapies. We conducted a phase II trial to evaluate the efficacy and safety of the combination of S-1 and irinotecan plus bevacizumab as a second-line treatment for oxaliplatin-refractory mCRC.
Methods: Patients with mCRC who were previously treated with oxaliplatin-containing regimens were enrolled. Oral S-1 at a dose of 40 mg/m(2) was administered twice daily for 2 weeks, followed by a 1-week drug-free interval. Irinotecan at a dose of 150 mg/m(2) and bevacizumab at a dose of 7.5 mg/kg were administered on day 1. The primary endpoint was progression-free survival (PFS).
Results: Thirty-seven patients were enrolled, and 34 and 36 patients were assessed for response and safety, respectively. The overall response rate was 20.6 % (95 % confidence interval [CI] 8.7-37.9), and the disease control rate was 76.5 % (95 % CI 58.8-89.3). The median PFS was 5.6 months (95 % CI 3.8-7.0). The median overall survival was 16.4 months (95 % CI 8.1-20.0). The most common grade 3/4 adverse events included neutropenia (25.0 %), anorexia (22.2 %), anemia (16.7 %), and fatigue/malaise (16.7 %). The most common grade 3/4 adverse event of special interest for bevacizumab was hypertension (30.6 %). One treatment-related death caused by gastrointestinal bleeding occurred.
Conclusions: The findings suggest that the combination of S-1 and irinotecan plus bevacizumab is effective and tolerable as second-line chemotherapy for patients with oxaliplatin-refractory mCRC.
Higami S, Mukai M, Yokoyama D, Uda S, Abe R, Mamuro N J Gastrointest Oncol. 2023; 14(2):663-675.
PMID: 37201062 PMC: 10186548. DOI: 10.21037/jgo-22-899.
Zhang X, Duan R, Wang Y, Liu X, Zhang W, Zhu X Ther Adv Med Oncol. 2022; 14:17588359211068737.
PMID: 35069808 PMC: 8771434. DOI: 10.1177/17588359211068737.